TP53 and acute myeloid leukemia: Tumor protein (TP53) mutations are one of the worst poor prognosis markers of AML, often found coexisting with complex karyotypes, disrupting DNA damage repair and apoptosis, thus rendering AML cells resistant to chemotherapy-induced apoptosis [25].